Literature DB >> 19854495

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

Daniela E Matei1, Kenneth P Nephew.   

Abstract

Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA methylation inhibitors in combination with existing chemotherapeutic agents have the potential for overcoming acquired drug resistance, laying the foundation for this specific class of epigenetic drug in ovarian cancer clinical trials. The recent completion of phase I trials of decitabine has yielded important information on dosing schedules and biological endpoints for evaluating patient responses. In addition, epigenetic drug effects on pharmacodyamic targets are beginning to emerge, and predictive epigenetic biomarkers and next generation epigenome therapeutics are being developed for application in clinical settings for ovarian cancer patients. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19854495      PMCID： PMC2813995          DOI： 10.1016/j.ygyno.2009.09.043

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  119 in total

1.  Effects of 5-aza-2'-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937.

Authors:  V Attadia
Journal:  Leukemia       Date:  1993-05       Impact factor: 11.528

2.  Apoptosis of L1210 Leukemia Cells Induced by 3-Deazaadenosine Analogs: Differential Expression of c-myc, NF-Kappa B and Molecular Events.

Authors:  I.-K. Kim; C.-C.H. Li; H.A. Young; J.-H. Lee; H.-S. Kim; K. Pardhasaradhi; G.E. Garcia; P.K. Chiang
Journal:  J Biomed Sci       Date:  1997 Mar-Jun       Impact factor: 8.410

3.  p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.

Authors:  K Milde-Langosch; E Ocon; G Becker; T Löning
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

4.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

5.  Histone modifications silence the GATA transcription factor genes in ovarian cancer.

Authors:  C Caslini; C D Capo-chichi; I H Roland; E Nicolas; A T Yeung; X-X Xu
Journal:  Oncogene       Date:  2006-04-10       Impact factor: 9.867

6.  DNA hypomethylation and ovarian cancer biology.

Authors:  Martin Widschwendter; Guanchao Jiang; Christian Woods; Hannes M Müller; Heidi Fiegl; Georg Goebel; Christian Marth; Elisabeth Müller-Holzner; Alain G Zeimet; Peter W Laird; Melanie Ehrlich
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

7.  Cellular differentiation, cytidine analogs and DNA methylation.

Authors:  P A Jones; S M Taylor
Journal:  Cell       Date:  1980-05       Impact factor: 41.582

Review 8.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Authors:  J Sandercock; M K B Parmar; V Torri; W Qian
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

9.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Authors:  Joshua Z Press; Alessandro De Luca; Niki Boyd; Sean Young; Armelle Troussard; Yolanda Ridge; Pardeep Kaurah; Steve E Kalloger; Katherine A Blood; Margaret Smith; Paul T Spellman; Yuker Wang; Dianne M Miller; Doug Horsman; Malek Faham; C Blake Gilks; Joe Gray; David G Huntsman
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

10.  DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage.

Authors:  George S Watts; Bernard W Futscher; Nicholas Holtan; Koen Degeest; Frederick E Domann; Stephen L Rose
Journal:  BMC Med Genomics       Date:  2008-09-30       Impact factor: 3.063
View more
  45 in total

1.  Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy.

Authors:  Jacob D Kagey; Priya Kapoor-Vazirani; Michael T McCabe; Doris R Powell; Paula M Vertino
Journal:  Mol Cancer Res       Date:  2010-06-29       Impact factor: 5.852

Review 2.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Authors:  Shafqat Ali Khan; Divya Reddy; Sanjay Gupta
Journal:  World J Biol Chem       Date:  2015-11-26

Review 3.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

Review 4.  MicroRNAs in brain tumors : a new diagnostic and therapeutic perspective?

Authors:  Richard Hummel; Jessica Maurer; Joerg Haier
Journal:  Mol Neurobiol       Date:  2011-07-08       Impact factor: 5.590

5.  The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.

Authors:  Fang Fang; Joanne Munck; Jessica Tang; Pietro Taverna; Yinu Wang; David F B Miller; Jay Pilrose; Gavin Choy; Mohammad Azab; Katherine S Pawelczak; Pamela VanderVere-Carozza; Michael Wagner; John Lyons; Daniela Matei; John J Turchi; Kenneth P Nephew
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

6.  Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.

Authors:  Sabrina L Samudio-Ruiz; Laurie G Hudson
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

Review 7.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

8.  Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors.

Authors:  Christian Huisman; G Bea A Wisman; Hinke G Kazemier; Marcel A T M van Vugt; Ate G J van der Zee; Ed Schuuring; Marianne G Rots
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

9.  Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.

Authors:  Chi-An Chen; Ying-Cheng Chiang; Ming-Cheng Chang; Yu-Hao Hu; San-Lin You; Yeu-Yao Kevin Cheng; Cheng-Yang Chou; Wen-Fang Cheng
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

10.  Epigenetic targeting of ovarian cancer stem cells.

Authors:  Yinu Wang; Horacio Cardenas; Fang Fang; Salvatore Condello; Pietro Taverna; Matthew Segar; Yunlong Liu; Kenneth P Nephew; Daniela Matei
Journal:  Cancer Res       Date:  2014-07-17       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.